After rising 43% in a month, is Oxford Nanopore now a top UK stock to buy?

Shares of Oxford Nanopore (LSE:ONT) have been surging recently. Is this a growth stock to buy for my portfolio after the firm’s H1 results today?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been hunting for a UK growth stock to buy recently. These tend to be a bit cheaper than their US counterparts and I reckon they could get a decent boost once the Bank of England starts cutting rates.

Today (24 July), Oxford Nanopore Technologies (LSE: ONT) posted a half-year trading update. The stock responded positively, rising 4% to 125p. This takes its gains to an incredible 43% in just the past month!

Zooming further out though, the share price is still down 79% since the innovative firm went public in 2021. So, is this the UK stock I’ve been looking for?

What it does

Firstly, a quick explanation about the name. The ‘Oxford’ part relates to it being spun out of Oxford University in 2005. The ‘Nanopore’ bit refers to the company’s novel technology that reads DNA using tiny holes, or nanopores, embedded in a membrane.

The firm’s devices are used in over 100 countries to understand the biology of humans, plants, animals, bacteria, viruses, and diseases like cancer. Its pocket-sized MinION device weighs under 100g and plugs into a laptop via a USB cable. This allows real-time sequencing anywhere, even in remote locations like jungles.

In 2023, over 2,800 research studies using Oxford Nanopore’s technology were published, reflecting its increasing importance across multiple fields.

Why has the stock struggled?

So, if the company’s tech is so cutting-edge, why is the share price down 79% in less than three years? Well, the firm lost £154.5m last year, wider than £91m the year before. That was almost the same as it reported in annual revenue (£170m). Yikes!

It isn’t expecting to break even on an adjusted EBITDA basis until the end of 2027. By that point, it reckons that its life science research tools (LSRT) gross margin will be 62%, up from 53.3% last year. Forecasts I’m looking at suggest revenue of £385m by 2027. So plenty of growth is expected here.

Unfortunately though, due to higher interest rates, the market is struggling to find the patience to wait that long for potential profits. Most loss-making growth stocks have plunged over the past two years.

Of course, investor sentiment is out of the company’s control. All it can do is continue to grow, innovate and stick to its medium-term schedule. And in H1, we saw evidence of progress.

Guidance reaffirmed

For the six months ended 30 June, it expects to report revenue of approximately £84m, broadly flat year on year at constant currency. However, underlying LSRT revenue (which strips out prior revenue from Covid and a large genome project), grew by 12.4%.

Growth was strongest across its PromethION franchise (benchtop sequencers), while the launch of multiple new products is expected to drive near and medium-term growth.

For the full year, it expects underlying revenue growth of 20%-30%, despite a challenging macroeconomic backdrop. And it expects gross margin to be approximately 57%, while its medium-term (2027) guidance remains intact.

My decision

The stock has a price-to-sales (P/S) ratio of 6.2. That’s more than US rivals Illumina (4.1) and Pacific Biosciences of California (2.4).

Oxford Nanopore is growing faster than those, but the stock still looks pricey. So, while I love this innovative British tech firm, I’m going to continue watching its progress from the sidelines (for now).

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Ben McPoland has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »

Growth Shares

As the boohoo share price falls, could it become a penny stock in 2025?

Jon Smith outlines some of the recent problems involving the boohoo share price and considers if things could get even…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

Here are the worst-performing FTSE 100 shares over the last 5 years

These five FTSE 100 shares have been complete duds over the last half decade. But is there potential for a…

Read more »

Investing Articles

Nvidia stock has tripled this year! Can it keep rising?

Nvidia's latest sales update showed strong growth and the stock's been on a tear so far in 2024. So is…

Read more »